Company profile: BioVaxys
1.1 - Company Overview
Company description
- Provider of immunotherapeutic cancer vaccines and delivery platforms. Haptenix uses haptens to train the immune system to recognize tumor or viral proteins; DPX is a lipid-based system for enhanced, sustained immune responses. Pipeline includes BVX-0918 (Phase I ovarian), Maveropepimut-S (DPX-formulated, Phase II for various cancers), and DPX SurMAGE (survivin/MAGE A9; bladder, lung, kidney; Phase I complete).
Products and services
- Maveropepimut-S (MVP-S): DPX-formulated cancer vaccine delivering antigenic peptides from survivin plus an immune activator and universal CD4 helper peptide, in Phase II development for diverse malignancies
- DPX™ Delivery Platform: Lipid-based encapsulation system engineered to sequester bioactive molecules, leading to enhanced and sustained immune responses in vaccine constructs
- Haptenix©: Hapten-based technology platform that uses chemical haptens to train immunity to recognize and target tumor or viral proteins, enhancing T cell responses against those antigens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioVaxys
Surface Oncology
HQ: United States
Website
- Description: Provider of next-generation cancer immunotherapy treatments based on proprietary insights into novel immunotherapy targets and emerging areas of cancer immuno-biology, advancing multiple preclinical programs with world-leading scientific founders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Surface Oncology company profile →
Neutec Pharma
HQ: United Kingdom
Website
- Description: Provider of biopharmaceuticals developing and manufacturing genetically recombinant antibody therapies and platform technologies. Products include Mycograb targeting heat shock protein 90 for systemic candidiasis; Aurograb targeting Staphylococcus aureus, including MRSA and VISA, used with vancomycin for MRSA; and FABTEC, a platform for identifying new therapeutic antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neutec Pharma company profile →
Curevo Vaccine
HQ: United States
Website
- Description: Provider of next-generation, non-mRNA vaccines for infectious diseases, developing Amezosvatein for the prevention of shingles and chickenpox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curevo Vaccine company profile →
Aimmune Therapeutics
HQ: United States
Website
- Description: Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aimmune Therapeutics company profile →
Bright Peak Therapeutics
HQ: Switzerland
Website
- Description: Provider of immunotherapies for cancer and autoimmune diseases, enabling tissue- and cell-specific cytokine targeting with enhanced efficacy. Offerings include Bright Peak Immunoconjugates combining optimized cytokines with antibodies; a chemical protein synthesis platform for novel proteins; and candidates such as BPT567 (PD1-IL18), BPT331 (PD1-IL2), and BPT331CAPS (PD1-IL2CAPS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bright Peak Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioVaxys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioVaxys
2.2 - Growth funds investing in similar companies to BioVaxys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioVaxys
4.2 - Public trading comparable groups for BioVaxys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →